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ABSTRACT
Chromatin immunoprecipitation (ChIP) fol-
lowed by sequencing of immunoprecipitated
DNA fragments is the highthroughput method
for identifying transcription factor binding sites.
In one such method, ChIPPET, pairedend di-
tags (PETs) derived from both ends of the im-
munoprecipitated DNA fragments are se-
quenced and mapped to the genome. We report
here the prediction of p53 target genes by meta
analyzing tags of p53 ChIPPET and by combin-
ing with other genomic annotations, using Gal-
axy, a webbased platform for largescale
genome analysis. We found 327 of p53 binding
sites on the genome of 5fluorouracil (5FU)
treated HCT116 colon cancer cells by searching
the total 65,509 PETs for PET clusters. The
search for p53 target gene, which focused on
PET clusters with computationallypredicted
p53 binding motif, identified 20 of putative p53
target genes as well as 11 of known p53 targets.
Another search for p53 target genes, which fo-
cused on PET clusters located within 50kb
flanking regions of transcription start sites of
genes, identified 278 of Refseq genes, 79 of non
coding RNAs and 5 of microRNAs as p53 tar-
gets which included lots of known validated tar-
gets. Our results indicate that sequencingbased
ChIP analysis combined with the existing
genome annotation is effective method to pre-
dict p53 binding loci and target genes, and also
show that the Galaxy platform is wellsuited for
multipletype analyses and visualization of ChIP
data, leading to functional annotation of tran-
scription factor binding sites.
Key words : Tags, Transcription factor binding site, Transcription start site, Genome database,
Genome browser
CORRESPONDENCE TO：
Takashi Tokino，Professor
Department of Molecular Biology，Cancer Research Institute，Sapporo Medical University
South １，West １７，Chuoku，Sapporo ０６０８５５６，Japan．
Email： tokino@sapmed．ac．jp
TEL： ０１１６１１２１１１ (ext ２３８６）
FAX： ０１１６１８３３１３
Prediction of p５３ target genes based on integrative analysis of chromatin
immunoprecipitated and sequenced tags，by using Galaxy，a webbased
interactive platform for largescale genome analysis
Tumor Res .４３,１－23（２００８） １
INTRODUCTION
The p53 gene, encoding for sequencespe-
cific nuclear transcription factors, is involved in
the maintenance of genome integrity by trans-
activating genes controlling cell cycle (p21/
CDKN2A, GADD45) and apoptosis (Bax, Fas,
Puma and Noxa) in response to cellular stress
signals1, 2). Many p53 target genes are currently
known, e.g. identified with microarray expres-
sion profiling3), and at the moment it is inten-
sively studied how p53 determines which target
genes to activate or repress in a certain stress
response1, 4). The microRNAs miR34a and miR
34b/c were also identified as direct, conserved
p53 target genes that presumably mediate in-
duction of apoptosis, cell cycle arrest, and senes-
cence by p5357). Since microRNAs may regulate
the levels of hundreds of different proteins8),
these findings add a new, challenging layer of
complexity to the p53 network. Notably, cancer
cells can escape the tumour suppression func-
tion of p53 through missense mutation of the
p53 gene or deregulation of p53 activity9). Since
p53 is the most frequently mutated tumor sup-
pressor gene in malignant tumors10, 11), identifica-
tion of the transcriptional targets of p53 is a key
to understanding functions of p53 and its signal-
ing pathways in tumorigenesis, and to exploiting
their potential molecular targets for cancer che-
motherapeutic drugs.
The tetrameric p53 protein binds to two re-
peats of a consensus DNA sequence RRRCWWGYYY
separated by a spacer of 013 bp, in which R =
purine, W = A or T and Y = pyrimidine12). This
motif is found in many identified p53 binding
sites within a few thousand base pairs of the
transcriptional start site (TSS) of p53 target
genes, and the motif, which binds p53 that can
regulate the transcription of the target genes, is
called p53 response element (RE). The progres-
sion of the human genome project set a trend of
computational approach to predict p53 binding
sites, and several algorithms have been devised
as follows: positionspecific score matrix
(PSSM)13) which attempts to estimate the bind-
ing affinity of a putative site; profile hidden
Markov models (PHMMs)14) which has been
trained on the existing data set of functional p53
REs, and can be used to score putative p53
binding sites; filtering by measurement of con-
servation of p53 REs among different species
based on comparative genomics15). However, in
silico predictions do not necessarily reflect the
actual target sites bound by p53 in vivo.
Chromatin immunoprecipitation (ChIP) has
been widely used to map the localization of
transcription factors on a specific gene locus.
The combination of ChIP assays with DNA mi-
croarray (ChIP on chip) has in recent years en-
abled the profiling of occupancy sites of tran-
scription factors including NFκB, myc and
p631618). p53 ChIPonchip data derived from
ENCODE regions19), from promoter regions2022),
or from regions covered by genomewide tilling
array23) suggested that there are between 300
and 3000 binding sites for p53 in the human
genome. More recently, Wei et al . has devel-
oped new methods using sequencing instead of
microarrays, termed ChIPPET (ChIP and
PairedEnd diTag sequencing)24). In ChIPPET
analysis, chromatin immunoprecipitation with
p53specific antibodies is carried out to collect
all of the tight binding sites for p53 in the
genome, subsequently, pairedend ditags (PETs)
derived from both 18bp ends of the immuno-
precipitated genomic DNA fragments are
cloned, sequenced and then mapped to the
genome. The ChIPPET analysis of 5
fluorouracil (5FU)treated human colon cancer
cell line HCT116, by sequencing approximately
66,000 PETs, identified 542 of p53 binding loci
throughout the genome24).
The combination of ChIP and fastmaturing
nextgeneration sequencing technology has
brought much excitement in the field of func-
tional genomics. In the newer method, ChIPse-
quencing (ChIPseq)2527), millions of immunopre-
cipitated DNA fragments are directly se-
quenced at one end for ～30 bp, and the short
sequence reads are then mapped to the refer-
ence genome. Comparing with ChIP on chip
whose usability for large mammalian genomes
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is limited by serious crosshybridization, se-
quencingbased ChIP analyses including ChIP
PET offer not only direct wholegenome cover-
age but also high signaltonoise ratio and sensi-
tivity that increase with sequencing depth. On
the other hand, these highthroughput sequenc-
ing analyses produce huge amount of tag data,
and the data analysis requires researchers to
have substantial programming experience and
data management skills. In ChIPPET data
analysis, tag clusters that represent in vivo lo-
cation of transcription factor binding sites, have
to be identified after the calculation of tag count
and tag positional distribution throughout the
genome.
Galaxy, a webbased interactive platform
for largescale genome analysis, combines the
power of existing genome annotation databases
with a simple web portal to enable users to
search remote resources, combine data from in-
dependent queries, and visualize the results28).
To allow experimental biologists with no pro-
gramming experience to easily and efficiently
manipulate genomic data, Galaxy provides vari-
ety of integrated Tools , e.g., a tool to extract
genomic data from popular sources of data like
the UCSC Table Browser and a tool to search
overlapping regions between two sets of
genomic intervals. Subsequently, as shown in
the Galaxy tutorial (http://screencast.g2.bx.psu.
edu/galaxy/promoters_SNPs/), relatively com-
plex analysis such as genomewide search of
promoters which have SNPs is easily imple-
mented. Furthermore, every step of user's
analyses is recorded in the Galaxy's history sys-
tem, and those workflows are able to be shared
with others.
We report here the prediction of p53 target
genes by metaanalyzing raw tag data of p53
ChIPPET and by combining with other
genomic annotations, using the Galaxy platform.
Our results indicate that sequencingbased
ChIP analysis combined with the existing
genome annotation is effective method to pre-
dict p53 binding loci and the candidate target
genes, and also show that Galaxy platform pro-
vides the sophisticated methods of analysis and
visualization of ChIP data.
MATERIALS AND METHODS
p53 related genomic data and databases
p53related genomic data was retrieved
from University of California Santa Cruz (UCSC)
Genome Browser website (http://genome.ucsc.
edu/, Mar. 2006 freeze, hg18), including: Gene
Identification Signature (GIS) determined by
chromatin immunoprecipitation (ChIP) and
PairedEnd diTag (PET) sequencing (GIS ChIP
PET)24), which shows the starts and ends of
genomic DNA fragments bound to p53 protein;
Conserved Transcription Factor Binding Sites
(TFBS) computed with the TRANSFAC29) Ma-
trix Database v7.0; the NCBI RNA reference se-
quences collection (RefSeq genes) ; UCSC
genes30); microRNAs from miRBase31); cytosine
phosphateguanine (CpG) islands.
GIS ChIPPET data contains position of
each PET on the genome, which was obtained
by the previous p53ChIPsequencing analysis
of HCT116 colon cancer cell line treated by 5
fluorouracil (5FU) for 6 h 24), as Browser Exten-
sible Data (BED)32)formatted data.
The TRANFAC database contains the loca-
tion and score of binding sites for various tran-
scription factors including p53, which was pre-
dicted by computational analysis of sequence
motif and conservation in the human/mouse/rat
alignment. The wholegenome localization of
p53 transcriptionfactor binding sites (p53
TFBS), was extracted from the TRANFAC da-
tabase using UCSC Table browser.
In the UCSC genes collection, transcripts
are categorized in four group, coding, noncod-
ing, antisense, or nearCoding as follows: a cod-
ing transcript is one where the evidence is rela-
tively good that it produces a protein; the near-
Coding transcripts overlap coding transcripts
by at least 20 bases on the same strand, but
themselves do not seem to produce protein
products because they are splicing variants
with introns after the stop codon, that therefore
undergo nonsense mediated decay33); antisense
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transcripts overlap coding transcripts by at
least 20 bases on the opposite strand; the other
transcripts, which are neither coding, nor over-
lapping coding, are categorized as noncoding
(http://genome.ucsc.edu/cgibin/hgGene?hgg_
do_txInfoDescription=1). In this study, we
termed the three types of transcripts other than
the coding transcripts in the UCSC data set,
“noncoding”RNA. Genomic position of tran-
scription start site (TSS) of each gene was ex-
tracted from Refseq or UCSC genes data sets.
From the miRBase database, we extracted
microRNAs with“hsa”names which signify the
human microRNAs. Each entry in the miRBase
Sequence database represents a predicted hair-
pin portion of a miRNA transcript, which are
not strictly precursor miRNAs (premiRNAs),
but include the premiRNA and some flanking
sequence from the presumed primary tran-
script.
Gene expression data of HCT116 colon cancer cells
Gene expression data of HCT116 cells
treated by hydroxyurea (GSM71424 and GSM
71436 from series GSE3176)34) was retrieved
from Gene Expression Omnibus (GEO) database
(http://www.ncbi.nlm.nih.gov/geo/). HCT116 ex-
pressing wildtype p53 (WT) and its derived iso-
genic p53/ (KO) cells were treated by 1.5 mM
hydroxyurea (HU) for 24 h, and gene expression
of each sample was analyzed by using NCI/
ATC HsOperonV2 microarray (GPL1528)
which contained 21,329 of 70mer oligonucleo-
tide probes34). Calibrated log2 expression ratio
(treated / untreated) of each gene was coordi-
nated to genomic position of each transcript,
and recorded as score for each genomic region
in Wiggle (WIG)32)formatted file by using a Perl
(Active Perl 5.8.8) script. The data of GIS PET
of polyA+ RNA (GIS PETRNA)35) for HCT116
cells treated by 5FU for 6 h, which shows the
starts and ends of fulllength mRNA tran-
scripts, was retrieved from the UCSC website.
Gene ontology data
Gene ontology (GO) terms for predicted p53
target genes were extracted by using High
Throughput GoMiner (http://discover.nci.nih.
gov/gominer/) tool and AmiGO (http://amigo.
geneontology.org/) database.
Galaxy
Genomic data was processed by Galaxy28)
(http://main.g2.bx.psu.edu/). Galaxy tools used
in this study, whose names are shown in italic
hereafter, are shown as follows: Get Data (UCSC
Main table browser) was used to retrieve data
from GIS ChIPPET, TFBS (TRANSFAC), CpG
island, Refseq genes, UCSC genes, microRNAs
and GIS PETRNA database and transfer to the
Galaxy work space; Operate on Genomic Inter-
vals (Cluster the intervals of a query) was used
to extract PET clusters which consist of more
than three PETs allowing 1 bp intervals be-
tween two PETs (termed PET3 clusters). Inter-
sect the intervals of two queries was used to
extract PET3 clusters with p53TFBS and/or
CpG island, and was used to find Refseq genes
and microRNAs which intersected with or were
flanked by a PET cluster. Get flanks was used
to obtain flanking genomic regions for PET clus-
ter and TSS of each gene at defined distance);
Graph/Display Data (Build custom track for
UCSC genome browser) was used to display
maps of PET clusters, p53TFBS, and expression
graph of each gene on Custom Tracks of the
UCSC genome browser in conjunction with ex-
isting browser data; Workflow was used to edit
and manage workflows for repeating Intersect
analyses by changing parameters. Selfexplana-
tory description for tool usage is also shown on
each tool 's web page.
RESULTS
p53 binding sites expected by search of PET3
clusters with p53 binding motif
To identify novel p53 target genes within
the human genome, we predicted p53 binding
sites by analyzing the existing data of chroma-
tin immunoprecipitation (ChIP) and PairedEnd
diTag (PET) sequencing (GIS ChIPPET)24) of
human colon cancer cell line HCT116 treated by
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5FU for 6 h, by using the Galaxy platform (Fig.
1). It has been shown that the PET clusters,
which consist of three or more overlapping
PETs, were highly specific for p53 ChIP enrich-
ment according to a Monte Carlo simulation24).
Therefore, we searched PET clusters which
consists of three or more overlapping or adja-
cent clusters within 1bp distance (termed PET3
Fig．１ Overview of Galaxy. A. The snap shots of the Galaxy main page (left) and the page of the workflow canvas
(right). The Galaxy main page consists of 3 frames including the“Tools”menu, the“History”that stores the
queries from each user, and the center page for data viewing. In the workflow canvas, selected items from
the history system is connected according to the order of analysis, and shown as an editable flowchart.
Some of parameters for Tools can be changed from the workflow canvas. B. The schematic of analysis us-
ing Galaxy. Each user inputs the initial genomic data for analysis into the history system, by retrieving from
any public genome databases or by uploading their own data (History 1). The initial data is analyzed by Tool
A and the result is stored in History 2. After a series of analyses, each user can visualize the result on the
UCSC genome browser, download the result (History 5), or save selected histories as a workflow and repeat
the analysis changing parameters.
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clusters) in the human genome for p53 binding
sites, by using the Galaxy tool Cluster (Fig. 2A,
C). In the preliminary analysis of total 4,133
PETs on chromosome 6 (Fig. 3A, track“GIS
ChIPPET”), 19 of PET3 clusters were detected
(Fig. 3A, track “PET3_Cluster”). To predict the
p53 binding sites with high confidence, we used
the Galaxy tool Intersect (Fig. 2A,C) to search
Fig．２ Schematic strategies used to predict p53 target genes (A, B) and corresponding workflows (C,D). A. p53 tar-
get gene search focused on PET3 clusters with p53TFBS. PET3 cluster (black bar) is the genomic region de-
fined by three or more overlapping or adjacent PETs (vertical lines at both ends, sequenced tags; connect-
ing line, unsequenced interval). The flanking regions (dotted line) of PET3 clusters which have the p53TFBS
(vertical line) was searched for putative p53 target genes (open boxes, exon; connecting lines, introns). B. p53
target gene search focused on flanking regions of TSS. The flanking regions of TSS of gene were searched
for PET3 clusters. In the workflows (C for A, D for B), databases are shown in columns, and those available
from the UCSC genome browser web site are lightbluecolored. The name of the Galaxy tool used in each
step is shown in bold italic.
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Fig．３ p53 binding sites expected by search of PET3 clusters with p53 binding motif (p53TFBS). Map images are
generated by the UCSC Genome Browser. PET3 clusters and those with p53TFBS were determined by us-
ing the Galaxy Tools Cluster and Intersect , respectively. Representative results of whole chromosome 6 (A),
and the genomic region around p21/CDKN1A on chromosome 6 (B) are shown. The position of each PET is
shown in the track labeled“GISChIPPET”as a vertical line (A), or horizontal line with vertical lines at
both ends in the zoomedin view (B). PET3 clusters (purplecolored) are shown in the“PET3_Cluster”
track. The positions of computationallypredicted p53 binding sites are shown in the“p53TFBS" track.
PET3 clusters with p53TFBS are shown in the“PET3 x p53TFBS”track, coloredred. The known p53 re-
sponse element for p21/CDKN1A is shown in the“p21_promoter”track. Refseq genes are shown in dense
mode (A), or labeled and have exons as boxes and introns as lines with arrowheads pointing in the direction
of transcription (B).
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for PET3 clusters that contain p53 binding sites
(p53TFBS) which are predicted by computa-
tional motif search. We found that 2 out of 19
PET3 clusters on chromosome 6 had p53TFBS
(Fig. 3A,B, track“PET3 x p53TFBS”). Impor-
tantly, both PET3 clusters were located up-
stream of p21/CDKN1A loci, which is one of the
best characterized p53target gene (Fig. 3B).
Furthermore, the closest PET3 cluster with p53
TFBS was exactly overlapped with the known
promoter region of p21 36). These data suggest
that p53 binding sites are predicted with high
confidence, by search for PET3 clusters with
p53TFBS.
p53 target genes predicted by search focused
on PET3 clusters with p53TFBS
The wholegenome Cluster analysis of to-
tal 65,509 PETs identified 327 PET3 clusters on
the genome, and 31 (9.5%) of those have the in-
ternal p53TFBS (Table 1). To search for puta-
tive p53 target genes, we examined total 27,090
of Refseq genes if they overlap with the region
of PET3 clusters with p53TFBS or not, by using
the Galaxy tool Intersect. We found that 12
genes overlapped with PET3 clusters with p53
TFBS (Table 2), of which 6 genes including
AEN, BAX, KRT80, p21/CDKN1A, RPS27L and
ZMAT3 were previously reported p53 targets24).
To obtain positive evidence of the target genes,
we retrieved microarray gene expression data
of HCT116 expressing wildtype p53 (WT) and
Table１．PET３ clusters with p５３TFBS
Chromosome Start（bp） End（bp）
chr１ ９，１６３，５６１ ９，１６５，３８５
chr１ １１７，２２３，１３９ １１７，２２３，８５６
chr１ １７９，３３４，９５３ １７９，３３５，８０８
chr１ １７９，３７０，１７１ １７９，３７１，５５７
chr２ ７０，６７６，７１４ ７０，６７８，５１７
chr３ １８０，２６９，９４８ １８０，２７１，３４５
chr３ １９５，２０３，１９５ １９５，２０４，９７０
chr４ １５７，９１１，３７７ １５７，９１２，８７２
chr４ １８８，０７８，５８５ １８８，０７９，６８１
chr５ ５７，７９３，１４３ ５７，７９４，３３１
chr５ １１８，６８７，０５５ １１８，６８８，０９１
chr５ １７３，６８８，０６９ １７３，６８９，１５８
chr６ ３６，７４２，６７４ ３６，７４３，６４２
chr６ ３６，７５１，９０１ ３６，７５４，５０２
chr７ １２３，６７３，３３２ １２３，６７４，４１４
chr８ １２８，８７５，６０３ １２８，８７７，９０１
chr８ １４３，８９３，７０７ １４３，８９４，６５５
chr９ １１７，７４５，２０８ １１７，７４６，８８６
chr９ １３８，５６３，８１２ １３８，５６５，１３２
chr１０ ６７，０４４，２７９ ６７，０４５，６０４
chr１１ ３４，６６３，１１６ ３４，６６４，２６３
chr１２ １９，４７５，４６９ １９，４７７，２８９
chr１２ ５０，８５５，９７５ ５０，８５６，９９０
chr１３ １０９，５７２，３８４ １０９，５７３，８４６
chr１３ １１３，５７２，５７７ １１３，５７３，９９６
chr１４ ３６，３５９，０５８ ３６，３６０，４１９
chr１５ ６１，２３５，８５５ ６１，２３７，６６０
chr１５ ８６，９６４，７８５ ８６，９６６，０８０
chr１８ ２２，２９４，３９０ ２２，２９５，５８２
chr１９ ４７，０５５，９２１ ４７，０５７，０５１
chr１９ ５４，１４９，４１５ ５４，１５０，５８０
Table２．Refseq genes overlapping with PET3 clusters with p53TFBS, or located on flanking
regions of PET3 clusters with p53TFBS
Position of Genes Genes*
Number of
genes
overlapping with PET3
clusters with p53TFBS
AEN, BAX, CDKN1A, GAS6, KCTD1, KRT80, PDGFC, RPS19, RPS27L,
SLC25A21, TNFAIP8, ZMAT3 １２
within ± 5 kb around PET3
clusters with p53TFBS
NOTCH1, PLK2
２
within ± 15 kb around PET3
clusters with p53TFBS
AEBP2, DHDH, DMRTC2, FTL, GYS1, IER5, LACTB
７
within ± 30 kb around PET3
clusters with p53TFBS
ARHGEF1, C5orf29, CD79A, COL4A1, EHF, FAM70B, GML, ISG20, LY6D,
LYPD4 １０
Total ３１
*Genes redundant in longer flanking regions are omitted．Previously known p５３ targets are in italic．
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p53knockedout (KO) cells treated by DNA
damaging reagent hydroxyurea (HU) from the
GEO database34), and visualized each expression
value (log2 intensity ratio of treated / untreated)
as a graph together with corresponding gene
map on the UCSC genome browser. For exam-
ple, RPS27L37) and AEN38) (Fig. 4A,B) showed in-
creased expression in HCT116 WT cells but not
in KO cells, similar to other known target genes
BAX and ZMAT3 (data not shown). These data
suggest that p53 target genes are accurately de-
tected by the combined search for the position
of PET3 clusters with p53TFBS and expression
change of each gene specific to HCT116 WT
cells under DNAdamaging stress.
We next searched Refseq genes located on
Fig．４ p53 target genes identified by the search focused on PET3 clusters with p53TFBS. Map images are gener-
ated by the UCSC Genome Browser. Maps for genes which have PET3 clusters with p53TFBS on their
TSS, RPS27L (A) and AEN (B), and for genes which have PET3 clusters with p53TFBS in upstream of their
TSS, NOTCH1 (C) and PLK2 (D), are shown respectively. In each panel, calibrated log2 expression ratio
(HUtreated / untreated) of each gene in HCT116 WT and KO cells is plotted as bar graph in the vertical
direction ranging from1.5 to +1.5, in the tracks labeled“HU_24h_WT”and“HU_24h_KO”, respectively.
Magentacolored bar graph shows positive value, which means that the gene expression is increased in HU
treated cells. Bluecolored bar graph shows negative value, which means that the expression is decreased in
HUtreated cells. Width of each bar graph is coordinated to genomic position of each transcript. Other map
symbols are shown in the same manner as Figure 3.
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flanking regions of PET3 clusters with
p53TFBS since the p53 binding sites are often
distant from the locus of the p53 target gene on
the genome. Within 5kb flanking region of
PET3 clusters with p53TFBS, two known p53
target genes NOTCH139) and PLK240) were found,
and those expressions were increased specifi-
cally in HUtreated HCT116 WT cells (Fig. 4C,
D). By further expansion of search up to 30kb
flanking region of PET3 clusters with p53TFBS,
additional 17 genes were found, including the re-
ported p53 target genes COL4A124), GML41) and
IER542) (Table 2). These suggest that the p53 tar-
get genes are effectively detected by search for
flanking regions of PET clusters with p53TFBS,
and other genes picked up might be candidate
p53 targets worth being examined by molecular
biological experiment.
p53 target genes predicted by search focused
on flanking regions of transcription start
sites which have PET3 cluster
Although the target prediction focusing on
PET3 clusters with p53TFBS picked up some
putative and known p53 target genes, the num-
ber of PET3 clusters which have the internal
p53TFBS was relatively less (9.5%, 31/327), in
part due to incomplete list of p53TFBS in the
TRANSFAC database which is based on purely
computational prediction29). In order to screen
genomewide p53 target genes more compre-
hensively, we examined if Refseq genes have
PET3 clusters around their TSS or not, irre-
spective of p53TFBS (Fig. 2B,D), by using the
Galaxy tool Intersect. Out of total 27,090 Refseq
genes, we found 278 (1.0%) genes (excluding iso-
forms) have PET3 clusters within 50kb flank-
ing regions of their TSS (Table 3.), including 61
genes reported previously24, 43). Classification of
gene function based on gene ontology terms re-
vealed that 33.1% (92/278) of putative and
known p53 target genes were involved in bio-
synthesis or cellular metabolic process, in addi-
tion to known p53related functions including
apoptosis or cell cycle (9.7%, 27/278), chromatin
modification or DNA repair (3.6%, 10/278), and
cell growth or differentiation (15.5%, 43/278).
Analysis of positional distribution of PET3
clusters (Table 3, Fig. 5A) revealed that 22.3%
(62/278) of genes have PET3 clusters within 10
kb flanking regions of TSS, which included 27 of
reported p53 target genes. However, remaining
216 genes including 34 of reported p53 target
genes had PET3 clusters 10 to 50kb away
from TSS. These results suggest that p53 often
bind to regulatory region which is more than
10kb distant from TSS, and regulate gene ex-
pression.
To gain insight into the putative p53 target
genes, we calculated expression difference be-
tween HCT116 WT and KO cells treated by HU
for each gene according to the microarray
data34), and combined with the data of position of
PET3 clusters. By the combined plot analysis
(Fig. 5A), we found that a novel p53 target can-
didate DKFZP564O0823 that has PET3 cluster
46kb upstream of TSS was upregulated specifi-
cally in HCT116 WT cells (Fig. 6B). We also
found that a novel target candidate DDX60L
(DEAD (AspGluAlaAsp) box polypeptide 60
like) which has PET3 cluster in an intron 14kb
downstream of TSS was downregulated specifi-
cally in HCT116 WT cells (Fig. 6C). Further-
more, this analysis illustrated that the PET3
cluster overlapping with the TSS of the re-
ported p53 target TNFRSF10B (tumor necrosis
factor receptor superfamily, member 10b)44) is
shared by adjacent family genes, TNFRSF10C
and TNFRSF10D because their expressions
were similarly induced in HCT116 WT cells
(Fig. 6A,D). Taken together, these results indi-
cate that the combined analysis of TSS, p53
binding regions deduced by PET3 cluster, and
gene expression would provide comprehensive
prediction of p53 target genes, and also give in-
formation on common promoters shared by sev-
eral p53 target genes around a p53 binding site.
PET3 clusters which were not located within
50kb flanking regions of TSS of Refseq
genes
We next examined how many PET3 clus-
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ters were associated with the 278 of p53 target
genes which were picked up by the TSSfo-
cused analysis. Out of total 327 PET3 clusters
on the genome, 157 (48%) of PET3 clusters were
associated with the Refseq genes, that is, lo-
cated within 50kb flanking regions of TSS of
Refseq genes, while other 170 (52%) of PET3
clusters were not. By using the Galaxy Tool In-
tersect, 55 out of the remaining 170 PET3 clus-
ters were shown to be located more than 50kb
away from TSS but within the loci of Refseq
genes, which included 19 of reported p53 tar-
gets (ASTN2, CDKAL1, CTNNA3, ERBB4,
FRMD4A, GPR39, KIAA0564, NAV3, NEO1,
NLGN1, NR6A1, PHF14, PRKAG2, PTPRM,
SHROOM3, SLC4A10, TPO, USP34 and
Fig．５ p53 target genes predicted by the search focused on flanking regions of transcriptional start sites which
have PET3 cluster. A. Two hundred and seventyeight PET3 clusters, which were found within 50kb flank-
ing regions of TSS of genes, are plotted against positions from TSS (x axis) and geneexpression difference
for corresponding genes between HUtreated HCT116 WT and KO cells (y axis). PET3 clusters located in
the flanking regions of TSS of known p53 target genes are plotted as red triangles, and other PET3 clusters
for putative p53 target genes are plotted as black dots. Some plots are labeled by the gene names which are
closest to the corresponding PET3 clusters. B and C. Maps for putative p53 target genes identified by the
TSSfocused search combined with the analysis of expression difference. DKFZP564O0823 (B) and DDX60L
(C) have PET3 clusters upstream and downstream of their TSS, respectively. D. Maps for TNFRSF10 family
genes which are possibly upregulated by one p53 binding site．
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USP9X)24) (data not shown). Furthermore, by the
analysis combined with gene expression data,
we found that novel p53 target candidates
ANKS1B which has the PET3 cluster 280kb
away from TSS and were upregulated in
HCT116 WT cells (Fig. 6A), and SBF2 which
has the PET3 cluster 250kb away from TSS
and were downregulated in HCT116 WT cells
(Fig. 6B). The remaining 115 PET3 clusters
were not located on any regions within 50kb
franking regions of TSS, or on gene loci of Ref-
seq genes. These findings suggest that the ex-
pression of part of huge p53 target genes which
consist of many exons and long introns might
be regulated by p53 binding site distant from
TSS but within the genes loci.
p53target noncoding RNAs predicted by
search focused on flanking regions of tran-
scriptional start sites which have PET3 clus-
ter
Recent analyses of the mammalian tran-
scriptome have shown that the transcriptabun-
dant regions occupy more than half of the
genomic sequence45). To investigate the possibil-
ity that p53 regulate the expression of various
transcripts other than wellannotated mRNAs
which code proteins, we sought to look for PET3
clusters around TSS of RNAs other than coding
RNAs. The data set of UCSC genes30), which is a
moderately conservative set of gene predictions
and is based on RefSeq, Genbank, Consensus
Coding Sequences (CCDS) and UniProt data-
bases, has approximately five times as many pu-
tative noncoding genes as the RefSeq gene col-
lection. We searched within 10kb flanking re-
gions of TSS of noncoding RNAs (13,762 of to-
tal 66,803 transcripts, including 6,686 narrowly
defined noncoding transcripts, 6,295 nearCoding
transcripts and 781 antisense transcripts: see
the definition of each transcript in Materials and
Methods) in the UCSC genes collection for PET3
clusters, by using Galaxy tool Intersect. Out of
total 327 PET3 clusters on the genome, 31 (9.5%)
of PET3 clusters were found to be located
within 10kb flanking regions of TSS of non
coding RNAs. On the other hand, out of the
13,762 noncoding RNAs, 79 (0.6%) transcripts,
which include 44 of narrowlydefined noncoding
transcripts, 35 of nearCoding transcripts, and
none of antisense transcripts, had PET3 clusters
within 10kb flanking region of their TSS. For
example, PVT14648), which is also registered as a
noncoding RNA in the Refseq genes collection
and listed in Table 3, had the TSS overlapped
with PET3 cluster with p53TFBS (Fig. 7A). In
Fig．６ Gene maps of putative p53 targets ANKS1B (A) and SBF2 (B), which have PET3 clusters more than 50kb
distant from their TSS. See text for details.
１２ H．MITA et al.
addition, noncoding RNAs ANKRD19, CR605611
and AX721264, which are not registered in the
Refseq collection, had PET3 clusters within 10
kb flanking regions of their TSS, respectively
(Fig. 7B,C,D). Since noncoding RNAs often have
no corresponding probes on standard microar-
rays and therefore lack information on their ex-
pression, we retrieved the existing data of GIS
PETRNA, which shows the starts and ends of
fulllength mRNA transcripts, and whose num-
ber is rough indication of gene expression level.
PETRNAs of 5FUtreated HCT116 cells were
observed in the genomic regions corresponding
to PVT1 and ANKRD19 loci (Fig. 7A,B, track
Fig．７ Gene maps for putative p53target noncoding RNAs PVT1 (A), ANKRD19 (B), CR605611 (C) and AX721264
(D) and for the known p53target microRNA hsamir34a (E) and putative target hsamir572 (F), which
have PET3 clusters on TSS or in their upstream regions, respectively. See text for details.
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“GISPETRNA”), indicating that those 2 non
coding RNAs were expressed in 5FUtreated
HCT116 cells while no tags were observed in
CR605611 and AX721264. These data suggest
that expression of part of noncoding RNAs is
also regulated by p53 and induced by DNA
damage.
Putative p53target microRNAs which have
PET3 clusters in the upstream regions
MicroRNAs are essential posttranscrip-
tional regulators that determine cell identity
and fate, via mechanisms of cleavagedependent
RNA degradation of the transcript or miRNA
mediated translational repression of the target
transcript8). Primary transcripts of microRNAs
form a long hairpin loop, primiRNA, which is
processed by Drosha to form premiRNA. Pre
miRNA is exported to the cytoplasm where
Dicer cleaves off the hairpin loop to form a du-
plex that contains the mature 2124 nucleotide
microRNA. The mature miRNA is then incorpo-
rated into the RNAinduced silencing complex
to target the 3' untranslated region of the target
mRNA49, 50). Since aberrant expression of miR-
NAs can lead to diseases including cancer5153),
we sought to examine if microRNAs have PET3
clusters near their loci and are under p53 regu-
lation or not. Although microRNA belongs to
noncoding RNA, we noticed that UCSC genes
collection contains only one third of microRNAs
(approximately 200 microRNAs, data not shown).
Therefore, we analyzed the data of total 685 of
human microRNAs retrieved from the miRbase
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database31), which have information on predicted
hairpin portions of miRNA transcripts, but have
no information on exact transcription start sites
of primary transcripts.
Our search using the Galaxy tool Intersect
revealed that only one microRNA, hasmir34a,
which has been reported as the first p53target
microRNA57), has the PET3 cluster within 30
kbupstream flanking regions of the microRNA
(Fig. 7E). Expanded search revealed that two
microRNAs, hsamir572 (Fig. 7F) and hsamir-
1012 (data not shown) have PET3 clusters in
60 to 70kbupstream flanking regions of the
microRNAs, and additional two microRNAs hsa-
mir181a2 and hsamir181b2 have PET3
clusters in 90 to 100kbupstream flanking re-
gions of the microRNAs, respectively (data not
shown). We found only 5 (0.7%) of microRNAs
related to PET3 clusters while future studies on
exact TSS for each microRNA may change the
result because primary transcripts of noncod-
ing RNAs including microRNAs, which are
marked by trimethylated histone H3 lysine 36
(H3K36me3)54), seem to be quite huge and harbor
clusters of microRNAs. Actually, PVT1 locus
contained 3 microRNAs (hasmir1205, 1206,
and1207) while they are > 100kb distant from
the TSS of PVT1 and the PET3 cluster with
p53TFBS (Fig. 7A), suggesting that those 3 mi-
croRNAs could also be p53 targets.
DISCUSSION
In this report, we described the prediction
of p53 target genes based on the data of se-
quencing analysis of p53 ChIPPET, combined
with existing substantial genomic data by using
the Galaxy platform. We deduced total 327 of
p53 binding sites on the genome of 5FU
treated HCT116 cells by picking up PET3 clus-
ters, and subsequently predicted 278 of Refseq
genes, 79 of noncoding RNAs and 5 of microR-
NAs as p53 targets which included lots of
known validated targets, suggesting that our
analysis worked effectively. Although there are
approximately 130 of wellvalidated protein
coding p53 target genes24, 43), it is not fully under-
stood how many noncoding RNAs, which are
presumably much more than coding RNAs, are
regulated by p53. Since p53 ChIPPET and
ChIPseq analysis shows unbiased genome
wide information on p53 binding sites, accumula-
tion of p53 ChIP data under various conditions
(cell and tissue type, and the stress) would pro-
vide more comprehensive understanding of p53
targets including noncoding RNAs.
While ChIPPET has been a useful ap-
proach for identifying candidates, we first ex-
tracted PET3 clusters which contain computa-
tionallyexpected p53 binding sites (p53TFBS)
in their regions, in order to increase the prob-
ability of prediction. Unexpectedly, PET3 clus-
ters which have p53TFBS was less (9.5%). PET3
clusters associated with validated targets often
had no internal p53TFBS (Table 3), implying the
problem of computational expectation of p53
binding sites in the TRANSFAC database, that
is, the strength and predictive power of expec-
tation model is dependent on the sampling size
and quality of the training set. On the other
hand, the recent study using p53 ChIPonchip
employing highresolution tiling arrays with an
average probe spacing 100bp, reported high
confidence motif that was contained in 83% of
all binding sites23). Future studies such as p53
ChIPseq would provide higherresolution data
which serve as a valuable knowledgebase for
p53 binding sites to clarify the p53 binding motif.
Our combined analysis of positional distri-
bution of PET3 clusters with change of gene ex-
pression after DNA damage (Fig. 6A) showed
that 216 of genes including 34 of reported p53
target genes had PET3 clusters 10 to 50kb
away from TSS, and in part, expression of those
is likely to be regulated by p53. Generally, the
p53 RE in a gene is most commonly located in
the 5' promoterenhancer region of the gene (～
50%) or in intron 1 (～25%)43). More rarely it is lo-
cated in introns 2 or 3 of a gene. Therefore, in
addition to the distance between TSS and p53
binding sites, if PET3 cluster is found down-
stream of TSS and within the gene locus, taking
account of the exonintron structure of each
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gene would provide more sensitive prediction of
p53 targets. On the other hand, it is also known
that eukaryotic cells contain transcriptionfactor-
binding proteins that bind together sticky tran-
scription factors and can mediate DNA looping.
This process can bring distal transcriptionfac-
torbound binding sites close to the TATA box,
and can confer regulation. In case of p53, in the
absence of a proximal p53 RE, the p53cofactor
Sp1 has been reported to serve as a surrogate,
provided that the RE is present close to the
TSS and the distal p53 RE. An example of Sp1
mediated DNA looping may be found in MDM2,
where a functional singlenucleotide polymor-
phism (SNP), SNP309 T/G, within a cluster of
Sp1binding sites affects the level of regulation of
nearby oestrogen and p53 REs, and has been as-
sociated with an early onset of breast cancer in
premenopausal women55). Further investigation
will be necessary to determine exactly how and
when distant p53 REs regulate gene expression.
By using the Galaxy platform, we carried
out almost all of analyses in this study, except
for very limited data arrangement for gene ex-
pression and ontology. The whole or part of
data from the seven databases (GIS ChIPPET,
TRANSFAC, Refseq genes, UCSC genes, mi-
croRNAs, CpG islands and GIS ChIPRNA) was
easily retrieved by using the Galaxy tool Get
Data, and transferred into the Galaxy history
system without consuming any hard disk space
of our own computers. Furthermore, the results
of analyses were outputted to the UCSC
genome browser by a few clicks, and immedi-
ately, we were able to watch and explore the
scalable and intuitive genome map that illus-
trates the positional relation among PETs, PET3
clusters, p53TFBS, CpG islands and genes. The
Galaxy tool Intersect enabled us to found the
genomic regions which meet multiple conditions,
for example, the PET3 clusters which have an
internal p53TFBS and located on TSS of a gene.
Subsequently, we were able to predict p53 tar-
get genes by some different characterizations of
PET3 clusters. Surprisingly, the Galaxy tools for
the analysis of genomic fragments returned the
results very quickly, for example, the Galaxy
tool Cluster extracted 327 of PET3 clusters
from the total 65,509 PETs in just 15 seconds. In
recent studies of transcription factors by ChIP
seq analyses using nextgeneration sequencers,
various types of software (e.g. PeakFinder25),
SISSRs56) and FindPeaks 3.157)) have been devel-
oped to indentify tagenriched regions as tran-
scription factor binding sites. Although those
programs are equipped with refined statistical
algorithms for tagclustering, it seems to be too
hard for biologists to setup the environment, in-
stall and run the software by giving appropriate
commandline parameters. We think that the
Galaxy platform is a biologistfriendly tool of
first choice to analyze and overlook largescale
ChIP data.
In conclusion, we showed that the Galaxy
platform fits the analysis of ChIPPET data
combined with other genomic data. Progress of
ChIPseq studies will promote the evolution of
the Galaxy platform as a versatile genome
analysis tool and vice versa. Further studies are
warranted to validate the putative p53 target
genes experimentally.
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